Articles
-
3 weeks ago |
nature.com | Ellen Carney
Cardiovascular–kidney–metabolic (CKM) syndrome is categorized into 5 stages that range from stage 0 (no risk factors) to stage 4 (clinical cardiovascular disease in CKM syndrome). A new study by Sophie Claudel, Ashish Verma and coauthors validates this staging system by demonstrating that the risk of cardiovascular and all-cause mortality increases with CKM syndrome stage. “CKM syndrome stages 1 to 4 are associated with a graded increase in risk of cardiovascular mortality,” comments Verma.
-
2 months ago |
nature.com | Ellen Carney
A new study provides evidence of an antibiotic-responsive kidney microbiota that may influence the formation of kidney stones. Jose Agudelo and colleagues identified bacteria in mouse kidney samples, with a higher density in the medulla than in the cortex. Using RNA fluorescence in situ hybridization analysis, they also found bacterial DNA in human kidney samples; species richness was greater in the glomeruli than in the tubules.
-
Sep 3, 2024 |
nature.com | Ellen Carney
In patients with liver disease, sodium and fluid retention is often attributed to reduced effective blood volume, which stimulates the renin–angiotensin–aldosterone system (RAAS). However, not all patients show RAAS activation. New data suggest a potential aldosterone-independent mechanism of sodium and fluid retention in liver disease. The researchers conclude that activation of ENaC by bile acids is likely to contribute to Na+ and fluid retention in liver disease.
-
Jul 29, 2024 |
nature.com | Ellen Carney
Tertiary lymphoid organs (TLOs) are ectopic lymphoid structures with immunomodulatory effects that develop in chronic inflammatory conditions, including transplantation, cancer, autoimmune diseases and infections. Now, Martin Oberbarnscheidt and coauthors report that TLOs contribute to rejection of kidney allografts.
-
Jul 2, 2024 |
nature.com | Ellen Carney
Recent data from a pre-specified analysis of the SELECT trial show a beneficial effect of the glucagon-like peptide-1 receptor agonist (GLP1RA) semaglutide on kidney outcomes in patients with cardiovascular disease and overweight or obesity without diabetes. These findings were presented at the 61st European Renal Association Congress in Stockholm.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →